Published on in Vol 14 (2025)

This is a member publication of University of Washington

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/81293, first published .
Effectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase 3 CONVOKE Randomized Controlled Trial

Effectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase 3 CONVOKE Randomized Controlled Trial

Effectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase 3 CONVOKE Randomized Controlled Trial

Journals

  1. Gandhi A, Firmin R, Luther L, Wahid N, Parcher B, Brown J, Machniewska G, Hare B, Perocco S, Strauss G, Dorner-Ciossek C, Pratap A. Patient Perspectives on a Digital Therapeutic for Schizophrenia: A Qualitative Evaluation of an App for Negative Symptoms. Schizophrenia Bulletin Open 2025;6(1) View